Literature DB >> 15109211

Structural basis of hypoxic pulmonary hypertension: the modifying effect of chronic hypercapnia.

Katherine Howell1, Henry Ooi, Rob Preston, Paul McLoughlin.   

Abstract

Exposure to chronic hypoxia causes pulmonary hypertension and pulmonary vascular remodelling. In chronic lung disease, chronic hypercapnia frequently coexists with hypoxia and is associated with worsening of pulmonary hypertension. It is generally stated that pulmonary hypertension in these conditions is secondary to hypoxic vascular remodelling and that hypercapnia augments this remodelling thus worsening the hypertension. We review recent evidence which shows that although chronic hypoxia causes thickening of the walls of pulmonary arterioles, these changes do not lead to structural narrowing of the lumen by encroachment. Moreover, hypoxia leads to new vessel formation within the pulmonary vasculature and not loss of vessels as formerly thought. Such neovascularization may provide a beneficial adaptation by increasing the area of the gas exchange membrane. These novel structural findings are supported by recent reports that inhibitors of the RhoA pathway can acutely reduce pulmonary vascular resistance in chronically hypoxic lungs to near normal values, demonstrating that structural changes are not the dominant mechanisms underling hypoxic pulmonary hypertension. Chronic hypercapnia inhibits the development of hypoxic pulmonary hypertension, pulmonary vascular remodelling and hypoxia-induced angiogenesis. This last effect might be maladaptive, as it would prevent the potentially beneficial increase in gas exchange membrane area. These findings suggest that structural narrowing of the vascular lumen of resistance vessels is not the mechanism by which hypoxia and hypercapnia cause pulmonary hypertension in chronic lung disease.

Entities:  

Mesh:

Year:  2004        PMID: 15109211     DOI: 10.1113/expphysiol.2003.026765

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  9 in total

Review 1.  Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension.

Authors:  M Oka; K A Fagan; P L Jones; I F McMurtry
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

2.  Sleep-disordered breathing in children with chronic kidney disease.

Authors:  Reshma Amin; Neha Sharma; Khamisa Al-Mokali; Priya Sayal; Suhail Al-Saleh; Indra Narang; Elizabeth Harvey
Journal:  Pediatr Nephrol       Date:  2015-07-09       Impact factor: 3.714

Review 3.  Endothelial cell metabolism in health and disease: impact of hypoxia.

Authors:  Brian W Wong; Elke Marsch; Lucas Treps; Myriam Baes; Peter Carmeliet
Journal:  EMBO J       Date:  2017-06-21       Impact factor: 11.598

4.  Mitogen-activated protein kinase phosphatase-1 is a key regulator of hypoxia-induced vascular endothelial growth factor expression and vessel density in lung.

Authors:  Kristin M Shields; Evgeniy Panzhinskiy; Nana Burns; W Michael Zawada; Mita Das
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

5.  Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension.

Authors:  Thomas A White; Tyra A Witt; Shuchong Pan; Cheryl S Mueske; Laurel S Kleppe; Eric W Holroyd; Hunter C Champion; Robert D Simari
Journal:  Am J Respir Cell Mol Biol       Date:  2009-07-31       Impact factor: 6.914

6.  Direct Extracellular NAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling. Transcriptional Regulation by SOX and HIF-2α.

Authors:  Xiaoguang Sun; Belinda L Sun; Aleksandra Babicheva; Rebecca Vanderpool; Radu C Oita; Nancy Casanova; Haiyang Tang; Akash Gupta; Heather Lynn; Geetanjali Gupta; Franz Rischard; Saad Sammani; Carrie L Kempf; Liliana Moreno-Vinasco; Mohamed Ahmed; Sara M Camp; Jian Wang; Ankit A Desai; Jason X-J Yuan; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2020-07       Impact factor: 6.914

7.  Sleep-Disordered Breathing in 2 Pediatric Patients on Peritoneal Dialysis.

Authors:  Neha Sharma; Elizabeth Harvey; Reshma Amin
Journal:  Perit Dial Int       Date:  2016 Jan-Feb       Impact factor: 1.756

8.  MMP-10 from M1 macrophages promotes pulmonary vascular remodeling and pulmonary arterial hypertension.

Authors:  Pei-Ling Chi; Chin-Chang Cheng; Cheng-Chung Hung; Mei-Tzu Wang; Hsien-Yueh Liu; Meng-Wei Ke; Min-Ci Shen; Kun-Chang Lin; Shu-Hung Kuo; Pin-Pen Hsieh; Shue-Ren Wann; Wei-Chun Huang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

9.  Variations in alveolar partial pressure for carbon dioxide and oxygen have additive not synergistic acute effects on human pulmonary vasoconstriction.

Authors:  Quentin P P Croft; Federico Formenti; Nick P Talbot; Daniel Lunn; Peter A Robbins; Keith L Dorrington
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.